Join Here   |   Log In

Inflammatory Bowel Disease (IBD): Crohn’s, Ulcerative Colitis, Genes, and Gut Microbes

Key takeaways:

  • Inflammatory bowel diseases (IBD), including Crohn’s and ulcerative colitis, are chronic gastrointestinal disorders that are serious, life-altering diagnoses.
  • Genetic variants play a big role in susceptibility to IBD, in combination with environmental factors.
  • Alterations in the way the immune system interacts with the gut microbiome cause inflammation in the intestines.
  • Knowing which genetic variants you have may help you figure out which lifestyle changes would be most helpful.
Members will see their genotype report below and the solutions in the Lifehacks section. Consider joining today

What is Inflammatory Bowel Disease?

IBD (inflammatory bowel disease) is a general term that encompasses two chronic inflammatory conditions of the gastrointestinal tract: Crohn’s disease and ulcerative colitis. [ref] These are characterized by chronic, relapsing-remitting inflammation of the gastrointestinal tract.

  • Crohn’s disease can affect any part of the GI tract, but it usually affects the small intestine.
  • Ulcerative colitis usually affects the colon and rectum.

The immune system seems to malfunction in IBD, causing inflammation in the GI tract. This eventually leads to the destruction of part of the intestines, causing pain, diarrhea, fever, malnutrition, and other symptoms.[ref]

Pathogenesis and Disease Mechanisms

A combination of genetic and environmental factors is thought to cause IBD.  The pathophysiology of IBD involves complex interactions between multiple factors:

Immune Dysregulation:
In IBD, there is a disruption of the mucous lining in the intestines, which changes the gut microbiome and causes an inflammatory response and immune dysregulation.[ref]

Intestinal macrophages play critical roles in mucosal immunity, microbial surveillance, and tissue repair. When the gut microbiome shifts so that there are more Bacteroides fragilis, a toxin is released that modifies macrophages and promotes an inflammatory shift in the macrophages.[ref]

B Cell and T Cell Involvement:
B cells and T cells are types of white blood cells that are part of the innate immune response. IBD used to be viewed as primarily T cell-driven,  but accumulating evidence demonstrates critical roles for B cells.[ref]

Environmental factors:
Diet, lifestyle, smoking, and medications can all be part of the changes in the gut. These factors are things that other people can handle, but in IBD, the combination of environmental factors, genetic vulnerability, and the gut microbiome comes together to cause inflammation.

Related article: Emulsifiers, gut mucosa, and inflammation

NOD2: Genetic risk factor for IBD

NOD2, also referred to as CARD15, is a gene that encodes a protein (nucleotide-binding oligomerization domain-containing protein 2) that recognizes bacteria in order to initiate an immune response.[ref]

NOD2 interacts with components found on both Gram-positive and Gram-negative bacteria found in your colon. It can also detect single-stranded RNA from viruses. Your gut microbiome interacts with your immune system in many ways. NOD2 plays an essential role in the way that the immune system keeps gut microbes in the right place and at the right levels in the colon. When encountering bacterial components, NOD2 activates the NF-κB or MAPK signaling pathways, which causes an inflammatory response that balances and keeps the microbial composition in the gut under control.[ref][ref]

When NOD2 is impaired, the gut microbiome is often not in homeostasis. There is an impaired clearance of bacteria.  The loss of this regulatory factor in the intestines increases the risk of IBD.[ref]

NOD2 was first identified in genetic studies in 2001, and it is consistently found to be important in the development of IBD. When NOD2 is impaired, it results in the upregulation of alternative inflammatory pathways, including the activation of the NLRP3 inflammasome in the intestinal barrier.[ref]

Screenshot from https://pmc.ncbi.nlm.nih.gov/articles/PMC10069614/

Other genetic risk factors for IBD:

Genes that are associated with altered gut microbiome composition are strongly tied to IBD risk. And genetic variants that alter the inflammatory response can also play a role in both the development and severity of IBD.

TLR4:
TLR4 (toll-like receptor 4) is a pattern recognition receptor that recognizes certain bacteria and promotes an inflammatory response. Levels are usually low in the intestinal barrier of healthy individuals, but it is upregulated in IBD, contributing to the inflammation. Variants that increase TLR4 are associated with an increased relative risk of IBD.[ref]

IL26:
IL-26 (interleukin-26) is a proinflammatory cytokine in the IL-10 family. It is often upregulated in the lining of the intestines in IBD. It is produced by activated T cells, especially Th17 cells, and signals for increased inflammation.[ref]

NLRP3:
The NLRP3 inflammasome is activated by cell damage or by pathogens in the gut. When activated, it triggers the production of inflammatory cytokines, such as IL-1β and IL-18. Variants in the CAIS1 gene that encode NLRP3 are associated with IBD risk.[ref]

 


IBD Genotype Report:

Access this content:

An active subscription is required to access this content.

Join as a member



Lifehacks:

Diet and Lifestyle Actions:

Increasing short-chain fatty acids, impacting NOD2:

NOD2 can be upregulated in the intestines by butyrate.[ref] Butyrate is a short-chain fatty acid produced by certain gut bacteria and also found in small amounts in foods such as butter and other full-fat dairy. Resistant starch (found in cooked and cooled potatoes and rice) feeds the kind of bacteria that produce butyrate.

Directly supplementing with sodium butyrate was shown in a placebo-controlled clinical trial to improve quality of life and decrease inflammation in IBD patients.[ref]

Vitamin D plays a role in stimulating NOD2.[ref] Get your vitamin D levels checked to see if you have sufficient levels. Sunshine is the natural way to boost your vitamin D levels, but you can supplement vitamin D if you can’t get enough sun to boost your levels. I like the ones that are coconut oil-based.

Related article: Learn more about vitamin D.

Genetic interactions with Ergothionine:

A common food that can be a problem for some people with IBD is mushrooms, according to a study involving mainly Crohn’s patients. Ergothioneine is a compound naturally synthesized by bacteria and fungi, including culinary mushrooms (white button, shiitake, portobello, and oyster). Ergothionine is a natural antioxidant, but people with genetic variants in SLC22A4 which increase the absorption of the antioxidant. In inflammatory bowel diseases, the excess antioxidant transport can be too much, tipping the balance.[ref]

Access this content:

An active subscription is required to access this content.

Join as a member



Related Articles and Topics:

TNF-alpha: Inflammation, Chronic Diseases, and Genetic Susceptibility

Leaky Gut Genes: Emulsifiers in Processed Foods

Is IBS genetic? Targeted Solutions, Based on Your Genes


References:

Ashton, James J., et al. “NOD2 in Crohn’s Disease—Unfinished Business.” Journal of Crohn’s & Colitis, vol. 17, no. 3, Aug. 2022, pp. 450–58. PubMed Central, https://doi.org/10.1093/ecco-jcc/jjac124.
Castillo, Francisca A., et al. “B Cells in Inflammatory Bowel Disease.” Immunology Letters, vol. 277, Feb. 2026, p. 107071. ScienceDirect, https://doi.org/10.1016/j.imlet.2025.107071.
Donnelly, Raymond P., et al. “Interleukin-26: An IL-10-Related Cytokine Produced by Th17 Cells.” Cytokine & Growth Factor Reviews, vol. 21, no. 5, Oct. 2010, pp. 393–401. PubMed Central, https://doi.org/10.1016/j.cytogfr.2010.09.001.
Kramer, Marcel, et al. “NOD2-C2 – a Novel NOD2 Isoform Activating NF-κB in a Muramyl Dipeptide-Independent Manner.” BMC Research Notes, vol. 3, Aug. 2010, p. 224. PubMed Central, https://doi.org/10.1186/1756-0500-3-224.
Leung, Chung-Hang, et al. “Butyrate Mediates Nucleotide-Binding and Oligomerisation Domain (NOD) 2-Dependent Mucosal Immune Responses against Peptidoglycan.” European Journal of Immunology, vol. 39, no. 12, Dec. 2009, pp. 3529–37. PubMed, https://doi.org/10.1002/eji.200939454.
Liu, Ziyue, et al. “The Role of NOD2 in Intestinal Immune Response and Microbiota Modulation: A Therapeutic Target in Inflammatory Bowel Disease.” International Immunopharmacology, vol. 113, Dec. 2022, p. 109466. ScienceDirect, https://doi.org/10.1016/j.intimp.2022.109466.
Lu, Yue, et al. “Toll-like Receptors and Inflammatory Bowel Disease.” Frontiers in Immunology, vol. 9, Jan. 2018, p. 72. PubMed Central, https://doi.org/10.3389/fimmu.2018.00072.
Petermann, Ivonne, et al. “Mushroom Intolerance: A Novel Diet–Gene Interaction in Crohn’s Disease.” British Journal of Nutrition, vol. 102, no. 4, Aug. 2009, pp. 506–08. Cambridge University Press, https://doi.org/10.1017/S0007114509276446.
Seyedian, Seyed Saeid, et al. “A Review of the Diagnosis, Prevention, and Treatment Methods of Inflammatory Bowel Disease.” Journal of Medicine and Life, vol. 12, no. 2, 2019, pp. 113–22. PubMed Central, https://doi.org/10.25122/jml-2018-0075.
Wang, Tian-Tian, et al. “Direct and Indirect Induction by 1,25-Dihydroxyvitamin D3 of the NOD2/CARD15-Defensin Beta2 Innate Immune Pathway Defective in Crohn Disease.” The Journal of Biological Chemistry, vol. 285, no. 4, Jan. 2010, pp. 2227–31. PubMed, https://doi.org/10.1074/jbc.C109.071225.
Yamamoto, Soichiro, and Xiaojing Ma. “Role of Nod2 in the Development of Crohn’s Disease.” Microbes and Infection / Institut Pasteur, vol. 11, no. 12, Oct. 2009, pp. 912–18. PubMed Central, https://doi.org/10.1016/j.micinf.2009.06.005.
Zhen, Yu, and Hu Zhang. “NLRP3 Inflammasome and Inflammatory Bowel Disease.” Frontiers in Immunology, vol. 10, Feb. 2019, p. 276. PubMed Central, https://doi.org/10.3389/fimmu.2019.00276.

About the Author:
Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.